Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analysts Evaluation and Price Targets for KimberlyClark Stock March 1 2024

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
FLO stock news
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Analysts’ Take on Kimberly-Clark Stock as of March 1, 2024

Analysts have recently shared their evaluations of Kimberly-Clark (NYSE: KMB), providing a range of opinions on the stock. Here is a breakdown of their ratings over the past 30 days and comparisons to previous months:

Total Ratings: Bullish (1), Somewhat Bullish (0), Indifferent (3), Somewhat Bearish (2), Bearish (0)
Last 30 Days: Bullish (1), Somewhat Bullish (0), Indifferent (0), Somewhat Bearish (0), Bearish (0)
1 Month Ago: No significant changes
2 Months Ago: Indifferent (3), Somewhat Bearish (1)
3 Months Ago: Somewhat Bearish (1)

Analyst Price Targets

Analysts’ 12-month price targets for Kimberly-Clark offer further insights:
Average Target: $125.0
High Estimate: $135.00
Low Estimate: $115.00
Change: Average target decreased by 1.96% from the previous average of $127.50.

Key Analyst Actions

Recent analyst actions and adjustments to ratings and price targets include:
– Jason English from Goldman Sachs maintains a Buy rating with a price target of $135.00.
– Lauren Lieberman from Barclays lowers the rating to Equal-Weight with a price target of $124.00.
– Nik Modi from RBC Capital lowers the rating to Sector Perform with a price target of $123.00.
– Andrea Teixeira from JP Morgan raises the rating to Underweight with a price target of $125.00.
– Anna Lizzul from B of A Securities lowers the rating to Underperform with a price target of $115.00.

Insights on Analyst Actions

Analysts adjust their recommendations based on market conditions and company performance, reacting to recent developments related to Kimberly-Clark.

Kimberly-Clark Corporation Stock Sees Slight Decrease But Pre-Market Activity Signals Potential Rebound

On March 1, 2024, Kimberly-Clark Corporation (KMB) saw a slight decrease in its stock price, closing at $121.17, which was $0.03 lower than the previous market close. This represented a 0.02% drop in price for the consumer goods company. However, there was a positive sign for KMB as the stock rose $0.88 in pre-market trading, indicating a potential rebound in the stock’s performance.

KMB’s stock performance on this day was notable for a few reasons. Firstly, the stock was trading near the bottom of its 52-week range, indicating that it may be undervalued compared to its recent performance. Additionally, KMB was trading below its 200-day simple moving average, which could be a bearish signal for some investors.

Despite the slight drop in price on March 1, the pre-market trading activity suggested that there was some positive momentum building for KMB. Investors may have been reacting to news or market conditions that could potentially drive the stock price higher in the near future.

Kimberly-Clark Corporation (KMB) Financial Results and Stock Performance Analysis – March 1, 2024

On March 1, 2024, Kimberly-Clark Corporation (KMB) saw its stock performances reflect its financial results, which were reported as follows:

Total revenue for the company stood at $20.43 billion for the past year, with a quarterly total of $4.97 billion. Despite the consistent revenue figures, the company’s net income tells a slightly different story. Kimberly-Clark reported a net income of $1.76 billion for the past year, with a quarterly net income of $509.00 million. This represents an 8.79% decrease in net income compared to the previous year, although it remained flat when compared to the last quarter.

Earnings per share (EPS) for Kimberly-Clark were reported at $5.21 for the past year and $1.50 for the last quarter. This indicates an 8.92% decrease in EPS compared to the previous year, with no change in EPS since the last quarter. The consistent EPS figures suggest that the company has been able to maintain its profitability on a per-share basis, despite the decrease in overall net income.

These financial results likely had an impact on Kimberly-Clark’s stock performance on March 1, 2024. Investors may have been cautious in light of the decrease in net income and EPS, despite the flat revenue figures. The stock may have experienced fluctuations throughout the day as investors digested the financial data and adjusted their positions accordingly.

It will be interesting to see how Kimberly-Clark continues to navigate the challenges in the market and whether they can improve their financial performance in the coming quarters. Investors will be keeping a close eye on future earnings reports to gauge the company’s progress and potential for growth.

Tags: KMB
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Title Cullinan Oncology Receives FDA Approval for Groundbreaking Cancer Therapy with CLN619 Antibody

Finance_Financing

HC Wainwright Co Reiterates Buy Rating on Argenx ARGX with 451 Price Target

Cleanest energy and ev

Mammoth Energy Services Reports Disappointing Quarterly Financial Results

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com